AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16040472 — intervention group
Group type: COMPARATOR
Intervention: Physician consultation alone (consultation group)
Number of subjects: 204
Study 16040472 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (combination and consultation)
Number of subjects: 204
Study 12015789 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg gliclazide MR tablet
Number of subjects: 0
Study 12015789 — intervention group
Group type: COMPARATOR
Intervention: 30 mg gliclazide MR tablet under fasted conditions
Number of subjects: 0
Study 12015789 — intervention group
Group type: COMPARATOR
Intervention: 30 mg gliclazide MR tablet under fed conditions
Number of subjects: 0
Study 10048061 — intervention group
Group type: EXPERIMENTAL
Intervention: New nerve root holders used during spinal decompression
Number of subjects: 0
Study 10048061 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral approach
Number of subjects: 0
Study 7552506 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2201941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone (4 mg/kg)
Number of subjects: 74
Study 2201941 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 74
Study 7318347 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100-200 mg/day)
Number of subjects: 36
Study 7318347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5-10 mg/day)
Number of subjects: 36
Study 7318347 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 36
Study 31015275 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling session, information booklet, continuous support by a researcher
Number of subjects: 140
Study 31015275 — intervention group
Group type: COMPARATOR
Intervention: Contact information of local support services
Number of subjects: 140
Study 29768070 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Help Program for Drug Abuse and Depression
Number of subjects: 74
Study 29768070 — intervention group
Group type: COMPARATOR
Intervention: In-person session with addiction therapist and treatment as usual
Number of subjects: 74
Study 29768070 — intervention group
Group type: COMPARATOR
Intervention: Treatment ordinarily offered in participating treatment centers
Number of subjects: 74
Study 27352487 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat-size moxibustion therapy (9 moxa cones on Zusanli (ST 36) and Feishu (BL 13) acupoints, once a day for 6 weeks)
Number of subjects: 70
Study 27352487 — intervention group
Group type: COMPARATOR
Intervention: Control group (follow-up visit without treatment)
Number of subjects: 70
Study 27352487 — intervention group
Group type: COMPARATOR
Intervention: Comparison of observation group vs control group after treatment
Number of subjects: 70
Study 25342209 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (12 week program with two group sessions and one home session per week, led by an experienced instructor, involving hatha yoga sequence with asana, pranayama, and meditation)
Number of subjects: 0
Study 25342209 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 0
Study 25342209 — intervention group
Group type: COMPARATOR
Intervention: No-treatment wait-list control group
Number of subjects: 0
Study 22719882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine (TDF-FTC)
Number of subjects: 301
Study 22719882 — intervention group
Group type: COMPARATOR
Intervention: Abacavir/lamivudine (ABC-3TC)
Number of subjects: 301
Study 20205950 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centred tobacco control program delivered over three home visits in the first three months of the infant's life.
Number of subjects: 0
Study 20205950 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) which does not receive the tobacco control program.
Number of subjects: 0
Study 17628251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear
Number of subjects: 75
Study 17628251 — intervention group
Group type: EXPERIMENTAL
Intervention: Jasper jumper
Number of subjects: 75
Study 17628251 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 75
Study 16199419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure controlled ventilation (PCV) with PEEP=5 cm H(2)O
Number of subjects: 20
Study 16199419 — intervention group
Group type: COMPARATOR
Intervention: Pressure controlled ventilation (PCV) without PEEP
Number of subjects: 20
Study 12005084 — intervention group
Group type: EXPERIMENTAL
Intervention: Menjugate vaccine
Number of subjects: 100
Study 12005084 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningitec vaccine
Number of subjects: 100
Study 12005084 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine vaccines only)
Number of subjects: 100
Study 10886586 — intervention group
Group type: EXPERIMENTAL
Intervention: 14G needle
Number of subjects: 100
Study 10886586 — intervention group
Group type: EXPERIMENTAL
Intervention: 16G needle
Number of subjects: 100
Study 10886586 — intervention group
Group type: EXPERIMENTAL
Intervention: 18G needle
Number of subjects: 100
Study 10886586 — intervention group
Group type: COMPARATOR
Intervention: All three needle sizes
Number of subjects: 100
Study 9118688 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors identified in logistic regression
Number of subjects: 400
Study 1560801 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (105 mg)
Number of subjects: 57
Study 1560801 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (111 mg)
Number of subjects: 57
Study 1560801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg)
Number of subjects: 57
Study 1560801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2862315 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (15 mg [50 000 IU] retinol, 200 mg riboflavine, and 50 mg zinc)
Number of subjects: 610
Study 2862315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 29926533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1185
Study 29426328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean lemonade
Number of subjects: 50
Study 29426328 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Tea
Number of subjects: 50
Study 29426328 — intervention group
Group type: COMPARATOR
Intervention: Flavored water control
Number of subjects: 50
Study 29426328 — intervention group
Group type: EXPERIMENTAL
Intervention: Study beverage (Mediterranean lemonade, Green Tea)
Number of subjects: 50
Study 29426328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood samples
Number of subjects: 50
Study 27281373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for SAD (CBT-SAD)
Number of subjects: 177
Study 27281373 — intervention group
Group type: COMPARATOR
Intervention: Light therapy (LT)
Number of subjects: 177
Study 23631951 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (CACR)
Number of subjects: 32
Study 23631951 — intervention group
Group type: COMPARATOR
Intervention: Computer games (CG)
Number of subjects: 32
Study 23288753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut technique of hamstring tendon harvesting
Number of subjects: 34
Study 23288753 — intervention group
Group type: COMPARATOR
Intervention: Push technique of hamstring tendon harvesting
Number of subjects: 34
Study 19013564 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 64
Study 19013564 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-DMPA users)
Number of subjects: 64
Study 18784156 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (600 mg weekly for 4 weeks, then 900 mg at week 5 and every 14 days thereafter)
Number of subjects: 87
Study 18784156 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 87
Study 18784156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 16608805 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 5
Study 12889683 — intervention group
Group type: EXPERIMENTAL
Intervention: High sense of coherence (SOC) tertile
Number of subjects: 4405
Study 12889683 — intervention group
Group type: COMPARATOR
Intervention: Low sense of coherence (SOC) tertile
Number of subjects: 4405
Study 12889683 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SOC tertile among white-collar workers
Number of subjects: 4405
Study 12889683 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SOC tertile among blue-collar workers
Number of subjects: 4405
Study 10781777 — intervention group
Group type: EXPERIMENTAL
Intervention: clarithromycin (500 mg)
Number of subjects: 24
Study 10781777 — intervention group
Group type: COMPARATOR
Intervention: trimethoprim-sulfamethoxazole (800/160 mg)
Number of subjects: 24
Study 8971284 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg nitroglycerine
Number of subjects: 8
Study 8971284 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg nitroglycerine
Number of subjects: 8
Study 8971284 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg nitroglycerine
Number of subjects: 8
Study 8971284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1280091 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 42
Study 1280091 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg o.d.
Number of subjects: 42
Study 1280091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31159799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower tourniquet pressure (SBP + 120 mmHg)
Number of subjects: 124
Study 31159799 — intervention group
Group type: COMPARATOR
Intervention: Conventional tourniquet pressure (SBP + 150 mmHg)
Number of subjects: 124
Study 28026887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 88
Study 28026887 — intervention group
Group type: COMPARATOR
Intervention: Left-lateral position
Number of subjects: 88
Study 28026887 — intervention group
Group type: COMPARATOR
Intervention: Right-lateral position
Number of subjects: 88
Study 28026887 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 88
Study 27125139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Mind and Body Therapeutic Program (MBT)
Number of subjects: 108
Study 24016370 — intervention group
Group type: EXPERIMENTAL
Intervention: CST PTP group (preclinical simulation course)
Number of subjects: 30
Study 24016370 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval group (clinical training + simulation training)
Number of subjects: 30
Study 24016370 — intervention group
Group type: COMPARATOR
Intervention: Control group (only clinical training)
Number of subjects: 30
Study 21246067 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyXTM Unicem (Ucem, self-adhesive) with MDP-based primer
Number of subjects: 40
Study 21246067 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyXTM ARC (ARC, conventional) with MDP-based primer
Number of subjects: 40
Study 21246067 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyXTM Unicem (Ucem, self-adhesive) with Rocatec system
Number of subjects: 40
Study 21246067 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyXTM ARC (ARC, conventional) with Rocatec system
Number of subjects: 40
Study 21246067 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyXTM Unicem (Ucem, self-adhesive) with no treatment
Number of subjects: 40
Study 21246067 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyXTM ARC (ARC, conventional) with no treatment
Number of subjects: 40
Study 21246067 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyXTM Unicem (Ucem, self-adhesive) with airborne-particle abrasion
Number of subjects: 40
Study 21246067 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyXTM ARC (ARC, conventional) with airborne-particle abrasion
Number of subjects: 40
Study 19671139 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg per day
Number of subjects: 80
Study 19671139 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 17096115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean women
Number of subjects: 46
Study 17096115 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body-obese (UBO) women
Number of subjects: 46
Study 17096115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body-obese (LBO) women
Number of subjects: 46
Study 17096115 — intervention group
Group type: COMPARATOR
Intervention: Obese women (UBO and LBO)
Number of subjects: 46
Study 15030422 — intervention group
Group type: EXPERIMENTAL
Intervention: CARTO
Number of subjects: 102
Study 15030422 — intervention group
Group type: COMPARATOR
Intervention: Conventional
Number of subjects: 102
Study 12370212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary transplantation of autologous mononuclear bone marrow cells (BMCs)
Number of subjects: 10
Study 12370212 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 10
Study 9532318 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga techniques (breathing and relaxation techniques, pranayama, yogasanas, meditation) taught three times a week for 16 weeks.
Number of subjects: 17
Study 9532318 — intervention group
Group type: COMPARATOR
Intervention: Nonyoga control group (no specific intervention details provided).
Number of subjects: 17
Study 7916004 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (14/190 mg)
Number of subjects: 18
Study 7916004 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 18
Study 7916004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2481883 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypervolaemic haemodilution with Hydroxyethyl starch 200/0.5 6%
Number of subjects: 37
Study 2481883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 5472804 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning glycaemia
Number of subjects: 162
Study 5472804 — intervention group
Group type: COMPARATOR
Intervention: Afternoon glucose tolerance tests
Number of subjects: 162
Study 5472804 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of diurnal variation
Number of subjects: 162
Study 31385636 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐AOMI
Number of subjects: 50
Study 31385636 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐AOMI
Number of subjects: 50
Study 31385636 — intervention group
Group type: EXPERIMENTAL
Intervention: AO
Number of subjects: 50
Study 28823491 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly two‐hour small group sessions led by an occupational therapist for six weeks focusing on nutrition, physical activity, and self‐management strategies
Number of subjects: 0
Study 25243910 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 25243910 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 25243910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25243910 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (300 mg and 150 mg)
Number of subjects: 0
Study 23022106 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐MDP‐containing luting system (Clearfil Ceramic Primer plus Panavia F 2.0)
Number of subjects: 40
Study 23022106 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐adhesive cement (Bifix SE)
Number of subjects: 40
Study 23022106 — intervention group
Group type: COMPARATOR
Intervention: Airborne particle abrasion with 25‐μm Al(2)O(3) particles
Number of subjects: 40
Study 23022106 — intervention group
Group type: COMPARATOR
Intervention: Airborne particle abrasion with 50‐μm Al(2)O(3) particles
Number of subjects: 40
Study 23022106 — intervention group
Group type: COMPARATOR
Intervention: Airborne particle abrasion with 110‐μm Al(2)O(3) particles
Number of subjects: 40
Study 23022106 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 1 - NT)
Number of subjects: 40
Study 20380784 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (CACR)
Number of subjects: 16
Study 19826172 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise comprising high intensity cardiovascular and resistance training, relaxation and body awareness training, massage, nine hours weekly for six weeks in addition to conventional care
Number of subjects: 269
Study 19826172 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 269
Study 19826172 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 269
Study 18051004 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide gel with potassium nitrate and fluoride (Opalescence 15% PF, OP)
Number of subjects: 32
Study 18051004 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide with amorphous calcium phosphate (Nite White 16%, NW)
Number of subjects: 32
Study 15510462 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoconjunctival technique
Number of subjects: 30
Study 15510462 — intervention group
Group type: COMPARATOR
Intervention: Routine technique
Number of subjects: 30
Study 11335905 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial photodynamic therapy with rotating and reciprocating optical fibers
Number of subjects: 3
Study 9440013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercise (PME) with biofeedback, performed three times per week for 12 weeks.
Number of subjects: 53
Study 9440013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PME instruction).
Number of subjects: 53
Study 9440013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercise (PME) with biofeedback.
Number of subjects: 53
Study 7890023 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (0.0125 mg per kg body weight)
Number of subjects: 25
Study 7890023 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.5 mg)
Number of subjects: 25
Study 7890023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study 2904824 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole 30 mg taken orally once daily for 1 week
Number of subjects: 0
Study 31854098 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-LIP
Number of subjects: 0
Study 31854098 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-HIP
Number of subjects: 0
Study 31854098 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-LIP
Number of subjects: 0
Study 31854098 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-HIP
Number of subjects: 0
Study 31854098 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-LIP
Number of subjects: 0
Study 31854098 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-HIP
Number of subjects: 0
Study 31854098 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 0
Study 31854098 — intervention group
Group type: COMPARATOR
Intervention: Control (no vaccine)
Number of subjects: 0
Study 30408456 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postpartum insertion of levonorgestrel contraceptive implants
Number of subjects: 183
Study 30408456 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of levonorgestrel contraceptive implants
Number of subjects: 183
Study 28780299 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective lead curtains (LC)
Number of subjects: 123
Study 28780299 — intervention group
Group type: COMPARATOR
Intervention: Nonprotective lead curtain (n-LC)
Number of subjects: 123
Study 25793928 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose RAI (1110 MBq)
Number of subjects: 102
Study 25793928 — intervention group
Group type: COMPARATOR
Intervention: High-dose RAI (3700 MBq)
Number of subjects: 102
Study 25793928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study 24011332 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 679
Study 24011332 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 679
Study 21138610 — intervention group
Group type: EXPERIMENTAL
Intervention: Magazine with food advertisements
Number of subjects: 47
Study 21138610 — intervention group
Group type: COMPARATOR
Intervention: Magazine with no food advertisements
Number of subjects: 47
Study 18551327 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Flex
Number of subjects: 184
Study 18551327 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 184
Study 17760282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile cueing using a vibrating electromechanical tactile vest activated in clockwise or counterclockwise direction during yaw rotation
Number of subjects: 15
Study 17760282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile cueing using a vibrating electromechanical tactile vest
Number of subjects: 15
Study 16266962 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide via Clickhaler (n=110)
Number of subjects: 222
Study 16266962 — intervention group
Group type: COMPARATOR
Intervention: Budesonide via Turbuhaler (n=112)
Number of subjects: 222
Study 11990435 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 10
Study 11990435 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (Control)
Number of subjects: 10
Study 10453668 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors of autologous origin, obtained by plasmapheresis
Number of subjects: 0
Study 10453668 — intervention group
Group type: EXPERIMENTAL
Intervention: No membrane or barrier technique
Number of subjects: 0
Study 8830061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone, 200 mg twice daily + Triazolam, 0.25 mg
Number of subjects: 102
Study 8830061 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam, 1 mg twice daily
Number of subjects: 102
Study 8830061 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam, 1 mg twice daily + Nefazodone, 200 mg
Number of subjects: 102
Study 8830061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam, 2 mg twice daily
Number of subjects: 102
Study 8830061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102